Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated *MGMT* gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial

Andrea Pace[1], Giuseppe Lombardi[2], Veronica Villani[1], Dario Benincasa[1], Claudia Abbruzzese[1], Ilaria Cestonaro[2], Martina Corrà[2], Giulia Cerretti[2], Mario Caccese[2], Antonio Silvani[3], Paola Gaviani[3], Diana Giannarelli[4] and Marco G. Paggi[1$]

[1] *IRCCS - Regina Elena National Cancer Institute, Rome, Italy*
[2] *Veneto Institute of Oncology IOV-IRCCS, Padua, Italy*
[3] *IRCCS Besta Neurological Institute, Milan, Italy*
[4] *Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy*

[$]**Corresponding author:**
Marco G. Paggi, MD, PhD
IRCCS - Regina Elena National Cancer Institute
Via Elio Chianesi 53, 00144 Rome, Italy
Tel.: +39-06-5266.2550; Email: marco.paggi@ifo.it

Abstract

Background. Glioblastoma (GBM) is a devastating brain tumor with poor prognosis, characterized by rapid growth and invasion into surrounding brain tissue. It is a hard-to-treat cancer and represents an unmet medical need. In recent years, there has been a growing interest in developing novel approaches to improve the outcomes of GBM patients; among these, drug repurposing. Our preclinical studies identified the antipsychotic chlorpromazine (CPZ) as an important modulator of signal transduction and energy metabolism in GBM cells, so we embarked on a Phase II clinical trial in which CPZ has been added to the standard disease treatment.

Methods. With these assumptions, we started a multicenter phase II clinical trial on newly diagnosed GBM patients carrying hypo-/un-methylated *MGMT* gene promoter by adding CPZ to temozolomide (TMZ) in the adjuvant phase of the standard first-line therapeutic protocol RACTAC schedule). Primary endpoints: Progression-Free Survival (PFS) and Combination treatment toxicity. Secondary endpoints: Overall Survival (OS) and Quality of Life (QoL)

Results. The RACTAC schedule showed an overall clinical benefit in GBM patients carrying hypo-/un-methylated *MGMT* gene promoter. When compared with historical cohorts, these patients displayed longer PFS, with toxicity described as a dose-dependent sedation and liver toxicity, both expected. One case of severe liver toxicity has been reported. OS and QoL are still under evaluation.

Conclusions. This clinical trial confirms the anticancer properties of CPZ, as described in several preclinical studies. In addition, the RACTAC study can be considered at least as a proof-of-concept in demonstrating the effectiveness of interfering with the well-described oncogenic monoamine signaling between neurons and GBM.

Keywords: Glioblastoma; Drug repurposing; Chlorpromazine; Phase II multicenter single-arm clinical trial.

45 ## Introduction

46 Glioblastoma (GBM) is the most frequent and severe brain tumor, characterized by poor
47 response to treatment and an almost certainty of relapse. First-line GBM treatment,
48 regardless of the molecular classification of the disease [1], consists in maximal surgical
49 resection followed by radiotherapy with concomitant temozolomide (TMZ) treatment,
50 followed by adjuvant TMZ administration. This scheme is however associated with a median
51 overall survival of 14.6 months and a 5-year survival <5% [2], a clinical course that clearly
52 denotes an unmet medical need.

53 Given its peculiar biological characteristics, GBM presents high invasive and infiltrative
54 properties [3], also coupled with a distinctive cellular heterogeneity, a prerequisite for a swift
55 adaptation under therapeutic pressure [4-7]. A key role in GBM resistance to therapy is played
56 by its ability to recover from genetic damages induced by radiotherapy and TMZ, by means
57 of an effective DNA repair, especially in tumors characterized by unmethylated O6-
58 methylguanine methyltransferase (*MGMT*) gene promoter [8]. Of note, GBM is among the few
59 tumors in which a single-drug treatment is currently in use, in contrast with most
60 therapeutic approaches in oncology and with its intratumor heterogeneity.

61 An interesting characteristic of GBM is its responsiveness to neurotransmitters, as
62 monoamines[9-11]. The well-known interplay between neurons and tumors, especially GBM
63 [10,12], and the more recent identification of a synaptic neuron-GBM connectivity confirms that
64 neuron-secreted mediators are taken up by GBM cells, where they act as oncogenic stimuli
65 [13]. These findings paved the way for considering the addition of selected neuroleptic drugs
66 as potentially effective addition to GBM treatment [14]. Indeed, Many psychotherapeutic
67 drugs, act on several post-synaptic receptors and display polypharmacological activity [14].

68 With these assumptions, we chose to evaluate the effects of one of the progenitors of
69 neuroleptic medications, i.e., the antipsychotic drug chlorpromazine (CPZ), in use for about
70 70 years for the therapy of several psychiatric disorders. CPZ is a compound listed in the
71 2021 WHO Model List of Essential Medicines[15].

72 Delving into CPZ pharmacodynamics *in vitro*, our group assayed its effects on established
73 and primary human GBM cells. The results defined the role of this drug in hindering GBM cell
74 growth by acting at different levels through multimodal antitumor effects without any action
75 on non-cancer neuroepithelial cells[16,17]. In addition, CPZ acts synergistically with TMZ in
76 hindering GBM vitality and stemness capabilities [16].

77 CPZ, besides not devoid of side effects, is a safe, low-cost and promptly available medication.
78 All these conditions paved the way for repurposing CPZ as an add-on drug in GBM therapy.
79 To this end, we planned the RACTAC (Repurposing the Antipsychotic drug Chlorpromazine as
80 a Therapeutic Agent in the Combined treatment of newly diagnosed glioblastoma) Phase II
81 multicenter single arm study, in which CPZ is added to adjuvant TMZ in the first-line therapy
82 of GBM patients whose tumor is characterized by an unmethylated *MGMT* gene promoter,
83 i.e., those characterized by resistance to TMZ and overall poorer prognosis [8].

84

Patients and Methods

Study design

This was a multicenter, prospective, single-arm clinical trial. The experimental procedure involved the combination of CPZ with standard treatment with TMZ in the adjuvant phase of the Stupp protocol [2] in newly diagnosed GBM patients carrying an unmethylated *MGMT* gene promoter. All patients received CPZ ("Largactil", from Teofarma S.R.L., Valle Salimbene (PV), Italy, as 25 mg tablets during the whole period of TMZ adjuvant treatment at a starting dose of 25 mg/day orally from day 1 of the TMZ adjuvant chemotherapy. The dosage was increased to 50 mg/day at the second cycle of treatment, if well tolerated, and continued for 6 cycles or until disease progression, death, unacceptable toxicity, or consent withdrawal (**Figure 1**).

This Phase II clinical trial has been approved by our Institutional Ethics Committee (Comitato Etico Centrale IRCCS - Sezione IFO-Fondazione Bietti, Rome, Italy) on September 6, 2019.

The study is registered as EudraCT #2019-001988-75 and ClinicalTrials.gov Identifier #NCT0422444. All patients provided informed written consent prior to participating in any study procedures or treatments.

Eligibility

Patients aged 18-75 years with newly diagnosed and histologically confirmed supratentorial GBM (World Health Organization grade 4) and unmethylated *MGMT* gene promoter status were eligible. Diagnosis of GBM was based on neurosurgical resection of the tumor or biopsy. . Additional inclusion criteria were: age ≥18 years; gadolinium-enhanced MRI ,48 h after surgery or before randomization; stable or decreasing dose of steroids for 1 week before randomization; Karnowski performance status(KPS) >70; satisfactory laboratory blood

108 and biochemical results within 2 weeks prior to randomization. Local assessment of O-6-
109 methylguanine-DNA methyltransferase (MGMT) methylation status on tumoral tissue was
110 required.

111 1.

112 ***Endpoints***

113 Progression-Free Survival (PFS) was the primary endpoint. PFS was defined as the time from
114 the start of the Stupp regimen (radiotherapy plus concomitant TMZ) to the earliest
115 documented date of disease progression, based on Response Assessment in Neuro-Oncology
116 (RANO) criteria [18,19], as determined by the investigator, death due to any cause, or censored
117 at the date of the last assessment. Evaluating a meta-analysis performed on 91 GBM clinical
118 trials, the choice of PFS as an endpoint can be considered appropriate as a surrogate
119 endpoint for earlier evaluation. The 6-mos PFS appears correlated with 1-year overall
120 survival (OS) and median OS [20].

121 Secondary endpoints were as follows: (i)Overall survival (OS; defined as the time from
122 diagnosis to the date of death from any cause or loss-to-follow-up; (ii) combination
123 treatment toxicity; adverse events (AEs) were evaluated according to the National Cancer
124 Institute's Common Terminology Criteria for Adverse Events version 5.0. Safety assessments
125 were performed from treatment initiation through 30 days after the last dose of
126 chemotherapy with TMZ plus CPZ; (iii) Quality of Life (QoL), assessed by means of the EORTC
127 QLQ C30+BN20 questionnaire at baseline and every 3 cycles [21,22].

128 ***Follow-up***

129 Patients were followed-up monthly during adjuvant chemotherapy, and every 3 months.
130 after completion of the standard treatment if the disease was stable. Radiological

assessment was done by gadolinium (Gd) brain MRI every 12 weeks from the first drug administration until disease progression.

Response assessment during study was based on investigators' evaluation using the RANO criteria [18,19], which included blinded MRI readings, assessment of neurological status, KPS scores, and steroid use.

Statistical analysis

All analyses were performed on the patients who received at least one dose of the study treatment. The primary objective of the study was to evaluate the proportion of patients free from progression after 6 months (PFS-6). Considering as unacceptable a percentage of PFS-6 (P0) equal to 35% and a desirable PFS-6 of 55% (P1), a minimum of 41 patients would be needed to guarantee a power of 80% at a significance level of 5% (one-sided), according to A'Hern [23]. If at least 20 patients were progression-free after 6 months, the treatment would be considered sufficiently active. All survival curves were estimated by the Kaplan-Meier method.

Clinical and demographic characteristics are reported as absolute counts and percentage when related to categorical items and as median and range if referred to quantitative variables.

149 ## Results

150 ***Patient characteristics***

151 Between April 2020 and August 2022, 45 patients who met the eligibility requirements and
152 consented to participate were screened. Forty-one patients received at least one cycle of
153 treatment and were included in the final analysis. Study follow-up was closed on December
154 31, 2022. Patients' baseline characteristics and demographics are summarized in **Table 1**.

155 Twenty patients (48,7%) completed 6 cycles of treatment with TMZ at standard dose plus
156 CPZ; twenty-one patients (51.2%) discontinued the treatment due to early progression
157 (mean cycles completed = 4.6). The median follow-up of was 15 months. (range 3–37).

158 ***Progression-free survival***

159 At 6 months, 27 patients were alive and without progression thus making possible the
160 achievement of the primary endpoint. Overall, 35 patients (85.4%) underwent disease
161 progression, with a median PFS of 8.0 months. (95% CI: 7.0-9.0) (**Figure 2A**). PFS at different
162 times is reported in **Table 2**.

163 ***Overall survival***

164 At the date of study closure, 29 deaths (69.7%) were observed, and median overall survival
165 has been 15.0 months (95% CI: 13.1-16.9). OS at different time-points is reported in **Figure**
166 **2B** and **Table 2**.

167 ***Toxicity***

168 . The RACTAC clinical experimentation has been correlated with the onset of an expected
169 dose-dependent sedation, especially at the beginning of the CPZ administration, and liver
170 toxicity (1 serious case), however expected for both CPZ and TMZ. Treatment was well
171 tolerated in all patients with mild somnolence (grade 1-2) in 8 (19,5%) and asthenia in 12

172 (29,2%) patients. In three patients, grade 3-4 hyper-transaminasaemia was observed (7%).

173 Adverse events lead to reduction or interruption of CPZ dosage in 4 patients (9,7%).

174 Decreased platelets count grade 3 was observed in one patient and neutropenia grade 3 in

175 one. All these data are summarized in **Table 3**.

176

177 ## Discussion

178 GBM patients with unmethylated *MGMT* promoter gene comprise 55-60% of total GBM
179 cases and present poorer prognosis due to an intrinsic resistance towards therapy with
180 alkylating agents. At present, while it is well recognized that TMZ brings a benefit in patients
181 with methylated *MGMT* gene promoter, it remains controversial whether this medication
182 should be administered or omitted when treating GBM patients with unmethylated *MGMT*
183 gene promoter. Indeed, EANO evidence-based guidelines on diagnosis and treatment of
184 diffuse gliomas of adulthood report that TMZ might only be active in GBM patients with
185 methylated *MGMT* gene promoter, whereas its effectiveness on patients with unmethylated
186 *MGMT* gene promoter appears modest [8,24].

187 Various therapeutic strategies have been investigated in several Phase II clinical trials, with
188 the aim to overcome drug resistance or to overpass DNA repair pathways in GBM patients
189 with unmethylated *MGMT* gene promoter [8,25]. In the same setting, addition of drugs other
190 than TMZ alone did not lead to encouraging results [26-28]. Other studies evaluated the efficacy
191 of new agents in replacement of TMZ in the first line treatment of GBM patients with
192 unmethylated *MGMT* gene promoter. In the EORTC 26082 Phase II trial, temsirolimus was
193 administered either during radiotherapy or as adjuvant treatment, showing no clinical
194 benefit [29]. In a single arm phase II trial, enzastaurin, a protein kinase C inhibitor, was
195 administered before, concomitantly with, and after radiotherapy to determine PFS-6 months
196 in GBM patients with unmethylated *MGMT* gene promoter, not achieving the primary
197 endpoint [30]. On the other hand, in the same setting, therapy with bevacizumab plus
198 irinotecan provides a PFS at 6 months better than TMZ, but with no improvement in OS [31].

199 Our results show that the addition of CPZ to standard TMZ in the first line treatment of GBM
200 patients with unmethylated *MGMT* gene promoter was safe and led to a longer PFS than the
201 one expected in this population of patients. A recent meta-analysis of pooled data from five
202 Phase III clinical trials reported PFS and OS a in patients with unmethylated *MGMT* gene
203 promoter of 4.99 and 14.11 months, respectively, when the standard-of-care GBM
204 treatment was used [32].

205 In our study, however, median OS was 15 months, thus not representing a clinically-relevant
206 improvement with respect to data reported in this meta-analysis. Such an outcome could
207 also relate to the administration of CPZ only in the adjuvant phase of treatment. Further
208 studies are needed to test the concomitant association of CPZ also during radiotherapy. The
209 safety profile of CPZ was consistent with its well-known pharmacological profile, even when
210 administered concomitantly with TMZ. In our study, the most frequent adverse event were
211 mild somnolence (grade 1-2) in 18% of patients, usually in the first month of treatment, and
212 fatigue, observed in 30% of patients, a symptom commonly reported within a range of 40-
213 70% in primary brain tumor patients[33].

214 Quality of life (QoL) is an important outcome to be evaluated in these GBM patients. It has
215 been measured, as specified above, by means of the EORTC QLQ-C30 and QLQ-BN20
216 questionnaires. Presently, these evaluations are in progress and the results will be published
217 shortly.

218 Most relevant limitations of RACTAC trial are the small number of patients included in the
219 study and the lack of a control group. However, the clinical characteristics of patients at
220 baseline seem to be representative of the real-world population of MGMT unmethylated

221 GBM. PFS6 observed in this trial was 8 months and resulted promisingly longer than that
222 reported in previous published trials in this population.

223 Since the plasticity of GBM and its ability to remodulate its cell population based on the
224 selective pressure generated by therapies, we can state that this tumor cannot be defined as
225 a "single-path disease", being therefore very unsatisfying to treat it by means of targeted
226 therapies. On these premises, it appears reasonable to consider the opportunity to use
227 "dirty drugs", i.e., drugs that are not too targeted, but are able to hit some generalized
228 vulnerabilities characterizing cancer cells.

229 CPZ is a well-known DRD2 antagonist [34] and therefore has been successfully used in the
230 treatment of psychiatric disorders. We intended to take advantage of its ability to interfere
231 with the function of DRD2, as well as a number of other neuromediator receptors
232 (https://go.drugbank.com/drugs/DB00477), to hamper the pseudo-synaptic, oncogenic
233 interplay between neurons and GBM.

234 Indeed, the results of the RACTAC clinical trial reported here can be considered at least as
235 proof-of-concept in supporting the effectiveness of interfering with the oncogenic
236 monoamine signaling between neurons and GBM. Of note, it should be considered that
237 there is also a profound interplay between peripheral/central nervous systems and cancer,
238 which acts through monoamine neuromediators and could represent a vulnerability
239 targetable through the use of repurposed neuropsychiatric drugs in oncology and appliable
240 to diverse cancers [35,36]. Evaluating the features of CPZ possibly useful in GBM treatment, we
241 could also consider a number of studies showing the ability of this drug to hinder GBM
242 malignant features in preclinical settings [37]. In the same context, during the course of the
243 RACTAC clinical trial, our group further refined the pharmacological effects of CPZ on GBM

cells *in vitro*, demonstrating the ability of this medication to hinder GBM malignant features at multiple levels [16,17] other than its known interference with the activity of neurotransmitters.

Considering the escalation of the costs of novel anticancer medications, the long time it takes for them to reach the market and the consequent nonavailability for a great number of patients, the use of repurposed drugs can dramatically cut down time and drug expenses for effective medications to reach the bedside, with significant benefits for the Health Systems. In addition, the characteristics inherent in repositionable drugs represent a further therapeutic chance for GBM patients for which no second-line therapy is currently established as effective or for those that have already experienced all known therapeutic opportunities.

Acknowledgments

Work partially financed by Funds Ricerca Corrente 2018-2019, 2020-2021, 2022-2023 from Italian Ministry of Health (MGP) and by the European Union - NextGenerationEU through the Italian Ministry of University and Research under PNRR - M4C2-I1.3 Project PE_00000019 "HEAL ITALIA" to Marco G. Paggi, CUP H83C22000550006. The views and opinions expressed are those of the authors only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the European Commission can be held responsible for them.

This paper is dedicated to the memory of our friend and colleague Armando Felsani, who recently passed away and who contributed so much to the advancement of knowledge in the field of cell differentiation and cell cycle regulation.

Editorial and graphical assistance were provided by Aashni Shah, Valentina Attanasio and Massimiliano Pianta (Polistudium SRL, Milan, Italy), and was supported by internal funds.

References:

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 2016; 131(6):803-820.

2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* 2005; 352(10):987-996.

3. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. *Nat Rev Cancer.* 2003; 3(7):489-501.

4. Lan X, Jorg DJ, Cavalli FMG, et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. *Nature.* 2017; 549(7671):227-232.

5. Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. *Genes Dev.* 2019; 33(11-12):591-609.

6. Couturier CP, Ayyadhury S, Le PU, et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. *Nat Commun.* 2020; 11(1):3406.

7. Hubert CG, Lathia JD. Seeing the GBM diversity spectrum. *Nat Cancer.* 2021; 2(2):135-137.

8. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med.* 2005; 352(10):997-1003.

9. Caragher SP, Hall RR, Ahsan R, Ahmed AU. Monoamines in glioblastoma: complex biology with therapeutic potential. *Neuro Oncol.* 2018; 20(8):1014-1025.

10. Caragher SP, Shireman JM, Huang M, et al. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. *J Neurosci.* 2019; 39(11):1982-1993.

11. Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. *Nature.* 2019; 573(7775):532-538.

12. Barygin OI, Nagaeva EI, Tikhonov DB, Belinskaya DA, Vanchakova NP, Shestakova NN. Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics. *Brain Res.* 2017; 1660:58-66.

295 **13.** Venkataramani V, Schneider M, Giordano FA, et al. Disconnecting multicellular networks in
296 brain tumours. *Nat Rev Cancer.* 2022.
297 **14.** Persico M, Abbruzzese C, Matteoni S, et al. Tackling the Behavior of Cancer Cells: Molecular
298 Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma. *Cells.* 2022;
299 11(2):263.
300 **15.** *World Health Organization Model List of Essential Medicines, 22nd List*. Geneva: World
301 Health Organization; 2021.
302 **16.** Matteoni S, Matarrese P, Ascione B, et al. Anticancer Properties of the Antipsychotic Drug
303 Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma
304 Proliferation In Vitro. *Front Oncol.* 2021; 11:635472.
305 **17.** Matteoni S, Matarrese P, Ascione B, et al. Chlorpromazine induces cytotoxic autophagy in
306 glioblastoma cells via endoplasmic reticulum stress and unfolded protein response. *J Exp Clin*
307 *Cancer Res.* 2021; 40(1):347.
308 **18.** Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-
309 grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol.* 2010;
310 28(11):1963-1972.
311 **19.** Radbruch A, Fladt J, Kickingereder P, et al. Pseudoprogression in patients with glioblastoma:
312 clinical relevance despite low incidence. *Neuro Oncol.* 2015; 17(1):151-159.
313 **20.** Han K, Ren M, Wick W, et al. Progression-free survival as a surrogate endpoint for overall
314 survival in glioblastoma: a literature-based meta-analysis from 91 trials. *Neuro Oncol.* 2014;
315 16(5):696-706.
316 **21.** Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and
317 Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical
318 trials in oncology. *J Natl Cancer Inst.* 1993; 85(5):365-376.

319 **22.** Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a
320 brain cancer quality-of-life questionnaire for use in combination with general cancer-specific
321 questionnaires. *Qual Life Res.* 1996; 5(1):139-150.
322 **23.** A'Hern RP. Sample size tables for exact single-stage phase II designs. *Stat Med.* 2001;
323 20(6):859-866.
324 **24.** Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and
325 treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol.* 2021; 18(3):170-186.
326 **25.** Weiler M, Hartmann C, Wiewrodt D, et al. Chemoradiotherapy of newly diagnosed
327 glioblastoma with intensified temozolomide. *Int J Radiat Oncol Biol Phys.* 2010; 77(3):670-
328 676.
329 **26.** Nabors LB, Fink KL, Mikkelsen T, et al. Two cilengitide regimens in combination with standard
330 treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene
331 promoter: results of the open-label, controlled, randomized phase II CORE study. *Neuro*
332 *Oncol.* 2015; 17(5):708-717.
333 **27.** Raizer JJ, Giglio P, Hu J, et al. A phase II study of bevacizumab and erlotinib after radiation
334 and temozolomide in MGMT unmethylated GBM patients. *J Neurooncol.* 2016; 126(1):185-
335 192.
336 **28.** Asano K, Fumoto T, Matsuzaka M, et al. Combination chemoradiotherapy with
337 temozolomide, vincristine, and interferon-beta might improve outcomes regardless of O6-
338 methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly
339 glioblastoma. *BMC cancer.* 2021; 21(1):867.
340 **29.** Wick W, Gorlia T, Bady P, et al. Phase II Study of Radiotherapy and Temsirolimus versus
341 Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma
342 without MGMT Promoter Hypermethylation (EORTC 26082). *Clin Cancer Res.* 2016;
343 22(19):4797-4806.

344 **30.** Wick W, Steinbach JP, Platten M, et al. Enzastaurin before and concomitant with radiation
345 therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed
346 glioblastoma without MGMT promoter hypermethylation. *Neuro Oncol.* 2013; 15(10):1405-
347 1412.
348 **31.** Herrlinger U, Schafer N, Steinbach JP, et al. Bevacizumab Plus Irinotecan Versus
349 Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase
350 Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. *J Clin Oncol.* 2016;
351 34(14):1611-1619.
352 **32.** Alnahhas I, Alsawas M, Rayi A, et al. Characterizing benefit from temozolomide in MGMT
353 promoter unmethylated and methylated glioblastoma: a systematic review and meta-
354 analysis. *Neurooncol Adv.* 2020; 2(1):vdaa082.
355 **33.** Valko PO, Siddique A, Linsenmeier C, Zaugg K, Held U, Hofer S. Prevalence and predictors of
356 fatigue in glioblastoma: a prospective study. *Neuro Oncol.* 2015; 17(2):274-281.
357 **34.** Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine
358 receptors. *Pharmacol Rev.* 2011; 63(1):182-217.
359 **35.** Magnon C, Hondermarck H. The neural addiction of cancer. *Nat Rev Cancer.* 2023.
360 **36.** Chang A, Botteri E, Gillis RD, et al. Beta-blockade enhances anthracycline control of
361 metastasis in triple-negative breast cancer. *Sci Transl Med.* 2023; 15(693):eadf1147.
362 **37.** Abbruzzese C, Matteoni S, Persico M, Villani V, Paggi MG. Repurposing chlorpromazine in the
363 treatment of glioblastoma multiforme: analysis of literature and forthcoming steps. *J Exp Clin*
364 *Cancer Res.* 2020; 39(1):26.

365
366
367
368

369 **Figure 1**



370

371 Scheme of the daily addition for of CPZ during the adjuvant phase of the first line protocol
372 for newly diagnosed GBM patients.

373

374 **Figure 2**



375



376

377 Kaplan-Meier curves describing PFS and OS trends in GBM patients with unmethylated
378 *MGMT* gene promoter treated according to the RACTAC protocol.

379

380 **Table 1**

381 Baseline characteristics of the enrolled GBM patients

382

	Baseline characteristics
Variables	Study population (n= 41)
Age at diagnosis (Median, y)	56 (range 20-75)
Gender	M 29 (70.7%)
KPS median	90 (range 70-100)
Extent of resection %	GTR 41.5; Partial 56.1; Biopsy 2.4
Steroid treatment at baseline # (%)	21 (51%)
Dexamethasone dose (mean)	4 mg

383

384 KPS=Karnofsky Performance status; GTR=Gross Total resection

385

386 **Table 2**

387 Progression-free survival (PFS) and overall survival (OS) in GBM patients with unmethylated
388 *MGMT* gene promoter treated according to the RACTAC protocol.

	6 months	12 months	18 months	24 months
PFS	68.3%	24.4%	12.4%	12.4%
OS	95.1%	72.0%	38.9%	25.5%

389

390

391 **Table 3**

392 Drug-related adverse events

Adverse events	Grade 1-2	Grade >2
Somnolence	8	-
Fatigue	11	1
Hypertransaminasemia	1	2
Thrombocytopenia	6	1
Neutropenia	1	1

393